
    
      A randomized, placebo-controlled, double-blind study of HemaMax to evaluate the safety,
      tolerability, pharmacokinetics, immunogenicity and pharmacodynamics of a single 12 Î¼g
      subcutaneous dose of HemaMax on 60 healthy subjects for 28 days after HemaMax administration.
    
  